• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2000 Fiscal Year Final Research Report Summary

IMMUNOGENE THERAPY WITH RADIATION SENSITIVE PROMOTOR IN A MOUSE BRAIN TUMOR MODEL

Research Project

Project/Area Number 09671453
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Cerebral neurosurgery
Research InstitutionJIKEI UNIVERSITY SCHOOL OF MEDICINE

Principal Investigator

KIKUCHI Tetsuro  JIKEI UNIV.SCHOOL OF MED., DEPARTMENT OF ONCOLOGY, LECTURER, 医学部, 講師 (60177798)

Project Period (FY) 1997 – 2000
KeywordsGLIOMA / B7 / ICAM-1 / MOUSE / ASTROCYTOMA / IL-12 / IMMUNOTHERAPY
Research Abstract

Mouse glioma cells transfected with ICAM-1 grew in T-cell deficient mice but not in syngeneic mice. Vaccination with ICAM-1-transfected tumor cells markedly inhibited the growth of subcutaneously inoculated gliomas but not gliomas located in the brain. In vivo antibody ablation study revealed that CD4^+ T, CD8^+ T and NK cells were all required to produce the antitumor effect of SR/ICAM-1. Transfecting mouse tumor cell lines with the B7 gene can lead to primary tumor rejection and the establishment of protective immunity. However, some studies have shown that the B7 effect upon T-cell dependent tumor immunity is limited. Therefore, we examined the antitumor effects of recombinant IL-12 and genetically engineered glioma cells expressing B7-1 or both B7-1 and ICAM-1. Vaccination of mice with B7-1-expressing tumor cells substantially inhibited the growth of subcutaneously inoculated gliomas but not those located in the brain. Vaccination with B7-1-expressing tumor cells and systemic rIL-12 was more effective than either B7-1-expressing tumor cells or rIL-12 alone. Our murine brain tumor model also showed that vaccination with tumor cells expressing both B7-1 and ICAM-1 combined with rIL-12 prolonged survival. In vivo antibody ablation study revealed that CD8^+ T cells were required to produce the antitumor effect of SR/B7-1/ICAM-1 and rIL-12. We have demonstrated the therapeutic potential of vaccination with rIL-12 and tumor cells expressing both B7-1 and ICAM-1 in the control of glioma growth.

  • Research Products

    (8 results)

All Other

All Publications (8 results)

  • [Publications] 菊池哲郎: "悪性脳腫瘍に対するインターロイキン12を中心とした免疫療法"神経免疫研究. 11. 54-59 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 菊池哲郎: "グリオーマの新しい免疫療法の試み"神経研究の進歩. 43. 443-450 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tetsuro Kikuchi: "Induction of antitumor immunity using intercellular adhesion molecule 1 (ICAM-1) transfection in mouse glioma cells"Cancer Letters. 142. 201-206 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tatsuhiro Joki: "Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12"International Journal of Cancer. 82. 714-720 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tetsuro Kikuchi: "IL-12-based immunotherapy against malignant gliomas"Journal of Neuro-Immunology. 11. 54-59 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tetsuro Kikuchi: "Novel immunotherapy against gliomas"Adv in Neurol Sciences. 43. 443-450 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tatsuhiro Joki: "Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1 ; CD54) transfection and recombinant interleukin 12"International Journal of Cancer. 82. 714-720 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tetsuro Kikuchi: "Induction of antitumor immunity using intercellular adhesion molecule 1 (ICAM-1)"Cancer Letters. 142. 201-206 (1999)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2002-03-26  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi